| Quarterly Financials | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 283 | 273 | 265 | 314 | 292 | 316 | 291 | 299 | 258 | 319 | 336 | 332 | 375 | 348 | 380 | 464 | 406 | 478 | 474 | 459 | 546 | 578 | 533 | 503 | 582 | 580 | 642 | 697 | 622 | 688 | 665 | 743 | 662 | 642 | 608 | 621 | 557 | 600 | 569 | 679 | 591 | 653 |
| Expenses | 240 | 230 | 226 | 269 | 244 | 265 | 247 | 253 | 223 | 267 | 282 | 274 | 322 | 300 | 328 | 403 | 351 | 409 | 410 | 378 | 411 | 462 | 425 | 421 | 500 | 506 | 545 | 608 | 555 | 614 | 593 | 649 | 577 | 565 | 536 | 534 | 490 | 531 | 495 | 583 | 516 | 569 |
| EBITDA | 44 | 42 | 40 | 45 | 48 | 51 | 43 | 46 | 36 | 53 | 54 | 57 | 54 | 47 | 52 | 61 | 55 | 69 | 64 | 81 | 135 | 117 | 108 | 82 | 81 | 74 | 97 | 89 | 67 | 74 | 72 | 94 | 85 | 77 | 72 | 87 | 66 | 69 | 74 | 95 | 74 | 84 |
| Operating Profit % | 15 % | 16 % | 15 % | 14 % | 16 % | 16 % | 15 % | 16 % | 14 % | 16 % | 16 % | 17 % | 14 % | 14 % | 14 % | 12 % | 13 % | 14 % | 13 % | 16 % | 25 % | 20 % | 20 % | 16 % | 14 % | 13 % | 14 % | 12 % | 11 % | 11 % | 11 % | 13 % | 13 % | 12 % | 12 % | 14 % | 12 % | 11 % | 11 % | 14 % | 13 % | 13 % |
| Depreciation | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 12 | 12 | 12 | 13 | 12 | 13 | 13 | 12 | 12 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 14 | 13 | 14 | 14 | 15 | 15 | 16 |
| Interest | 10 | 11 | 11 | 12 | 10 | 9 | 9 | 9 | 9 | 8 | 9 | 9 | 9 | 10 | 11 | 10 | 9 | 9 | 8 | 8 | 7 | 7 | 5 | 4 | 4 | 5 | 5 | 6 | 7 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 8 |
| Profit Before Tax | 25 | 23 | 23 | 25 | 29 | 33 | 24 | 31 | 17 | 35 | 35 | 38 | 34 | 27 | 31 | 40 | 34 | 48 | 43 | 61 | 116 | 97 | 90 | 65 | 65 | 56 | 79 | 71 | 48 | 53 | 50 | 73 | 64 | 56 | 52 | 64 | 44 | 46 | 51 | 71 | 51 | 60 |
| Tax | 8 | 7 | 6 | 6 | 9 | 11 | 6 | 9 | 5 | 11 | 12 | 14 | 10 | 9 | 10 | 12 | 11 | 16 | 15 | 2 | 31 | 22 | 22 | 14 | 16 | 14 | 20 | 15 | 13 | 14 | 13 | 17 | 16 | 17 | 15 | 17 | 11 | 11 | 14 | 8 | -3 | 15 |
| Net Profit | 17 | 16 | 17 | 19 | 20 | 22 | 18 | 22 | 11 | 24 | 23 | 24 | 23 | 18 | 21 | 27 | 23 | 32 | 28 | 59 | 85 | 75 | 68 | 52 | 49 | 43 | 58 | 55 | 35 | 39 | 37 | 56 | 48 | 40 | 37 | 47 | 33 | 35 | 37 | 63 | 54 | 45 |
| EPS in ₹ | 7.18 | 6.49 | 7.03 | 7.68 | 8.21 | 9.11 | 7.56 | 8.70 | 4.77 | 9.89 | 9.78 | 9.97 | 9.82 | 7.65 | 8.86 | 12.06 | 9.56 | 13.87 | 11.92 | 25.26 | 9.17 | 8.08 | 7.30 | 5.54 | 5.25 | 4.60 | 6.29 | 5.97 | 3.76 | 4.18 | 3.96 | 6.07 | 5.18 | 4.29 | 3.99 | 5.15 | 3.62 | 3.83 | 4.06 | 6.88 | 5.91 | 4.95 |
Aarti Drugs
Aarti Drugs
407.85
-2.85
(-0.69%)
Market Cap
₹- Cr
PE Ratio
-
Volume
1,27,399.00
Day High - Low
₹412.75 - ₹406.15
52W High-Low
₹564.05 - ₹312.00
Key Fundamentals
Market Cap
- Cr
EPS
-
PB Ratio
-
Book Value
159.78
EBITDA
-
Dividend Yield
- %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
-
Analyst Rating and Forecast
- By Refinitiv from1 analysts
Actual
Company News
View All News
Aarti Drugs reported quarterly revenue of ₹653 crores, representing 9% year-over-year growth. EBITDA increased 23% to ₹84 crores with margins improving to 12.9%. The company commissioned its Sayakha Amines plant to enhance self-sufficiency for Metformin production. The Tarapur Salicylic Acid production line is expected to reach 500 tonnes monthly capacity by Q4FY26. The company targets sustained double-digit growth through backward integration and export expansion, with plans to strengthen U.S. and EU regulatory approvals to drive high-value API exports and margin expansion over FY27-FY29.
Aarti Drugs Limited announced its audited financial results for the quarter and half-year ended September 30, 2025. The company reported standalone net profit of Rs 48.64 crores for Q2, compared to Rs 30.39 crores in the previous quarter, representing significant growth. For the half-year period, standalone profit reached Rs 90.42 crores versus Rs 57.30 crores in the prior year. Total income for Q2 stood at Rs 520.52 crores. The company's new manufacturing plant at Sayakha, Gujarat commenced commercial operations from September 4, 2025. An HCl gas leakage incident occurred at the T-160 unit on September 8, 2025, leading to voluntary suspension of that process as a precautionary measure, though it had no material financial impact. The company completed a buyback of 6.65 lakh equity shares at Rs 900 per share in September 2024, reducing paid-up share capital to Rs 91.27 crores.
Aarti Drugs delivered strong quarterly results with net profit jumping to 420 million rupees compared to 30 million rupees in the same period last year. The company's EBITDA increased to 752 million rupees from 595 million rupees year-over-year. EBITDA margin improved to 13% from 11% in the corresponding quarter of the previous year, indicating enhanced operational efficiency.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
790.15 | - | #1 - | - | - | - | - | 34.61 | |
699.20 | - | #1 - | - | - | - | - | 43.29 | |
64.57 | - | #1 - | - | - | - | - | 21.03 | |
554.80 | - | #1 - | - | - | - | - | 37.85 | |
28,850.00 | - | #1 - | - | - | - | - | 39.24 | |
42.05 | - | #1 - | - | - | - | - | 41.15 | |
54.60 | - | #1 - | - | - | - | - | 42.72 | |
5,001.00 | - | #1 - | - | - | - | - | 43.40 | |
414.10 | - | #1 - | - | - | - | - | 43.97 | |
26.95 | - | #1 - | - | - | - | - | 41.68 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,002 | 1,102 | 1,191 | 1,389 | 1,456 | 1,577 | 1,766 | 2,208 | 2,421 | 2,432 | 2,575 |
| Fixed Assets | 449 | 493 | 581 | 602 | 625 | 644 | 665 | 690 | 676 | 811 | 866 |
| Current Assets | 526 | 565 | 571 | 737 | 784 | 900 | 1,057 | 1,393 | 1,492 | 1,321 | 1,338 |
| Capital Work in Progress | 16 | 34 | 14 | 28 | 33 | 12 | 19 | 77 | 210 | 261 | 330 |
| Investments | 0 | 0 | 12 | 11 | 12 | 13 | 17 | 20 | 19 | 20 | 22 |
| Other Assets | 537 | 575 | 584 | 748 | 785 | 907 | 1,064 | 1,422 | 1,516 | 1,340 | 1,356 |
| Total Liabilities | 1,002 | 1,102 | 1,191 | 1,389 | 1,456 | 1,577 | 1,766 | 2,208 | 2,421 | 2,432 | 2,575 |
| Current Liabilities | 483 | 501 | 494 | 622 | 591 | 623 | 595 | 940 | 950 | 796 | 837 |
| Non Current Liabilities | 211 | 244 | 297 | 312 | 321 | 301 | 257 | 232 | 279 | 355 | 368 |
| Total Equity | 308 | 357 | 400 | 455 | 543 | 653 | 913 | 1,036 | 1,193 | 1,282 | 1,369 |
| Reserve & Surplus | 284 | 333 | 376 | 432 | 520 | 629 | 820 | 944 | 1,100 | 1,190 | 1,278 |
| Share Capital | 24 | 24 | 24 | 24 | 24 | 23 | 93 | 93 | 93 | 92 | 91 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -1 | 1 | -0 | 0 | 1 | 2 | 2 | 13 | -14 | -1 | -2 |
| Investing Activities | -107 | -99 | -107 | -74 | -62 | -33 | -72 | -150 | -164 | -224 | -165 |
| Operating Activities | 105 | 133 | 175 | 70 | 143 | 251 | 155 | 70 | 133 | 359 | 245 |
| Financing Activities | 2 | -33 | -68 | 4 | -80 | -215 | -81 | 92 | 17 | -136 | -82 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 60.20 % | 60.14 % | 60.12 % | 59.99 % | 59.83 % | 59.98 % | 59.77 % | 59.66 % | 59.58 % | 58.70 % | 58.56 % | 57.47 % | 57.13 % | 55.67 % | 55.64 % | 55.38 % | 55.48 % | 55.22 % | 54.72 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 2.33 % | 2.10 % | 2.56 % | 2.96 % | 2.50 % | 2.28 % | 2.25 % | 2.26 % | 2.69 % |
| DIIs | 1.59 % | 1.97 % | 2.09 % | 2.28 % | 2.69 % | 2.76 % | 3.16 % | 3.90 % | 4.09 % | 4.71 % | 5.32 % | 5.26 % | 5.99 % | 7.35 % | 7.84 % | 8.77 % | 9.70 % | 9.94 % | 9.90 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 31.86 % | 32.32 % | 32.68 % | 32.85 % | 32.02 % | 32.16 % | 26.66 % | 25.98 % | 25.72 % | 25.34 % | 24.65 % | 25.84 % | 25.11 % | 24.75 % | 24.80 % | 24.32 % | 23.51 % | 23.69 % | 23.58 % |
| Others | 6.36 % | 5.57 % | 5.11 % | 4.89 % | 5.46 % | 5.10 % | 10.41 % | 10.46 % | 10.61 % | 11.25 % | 9.14 % | 9.33 % | 9.20 % | 9.27 % | 9.21 % | 9.24 % | 9.06 % | 8.89 % | 9.11 % |
| No of Share Holders | 1,73,704 | 1,77,992 | 1,83,344 | 1,95,469 | 1,89,607 | 1,86,674 | 1,80,303 | 1,73,283 | 1,69,090 | 1,62,409 | 1,67,446 | 1,70,414 | 1,57,547 | 1,50,218 | 1,90,281 | 1,76,006 | 1,69,761 | 1,60,260 | 1,52,252 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1 | 1 | 1 | 2 | 2.5 | 1 | 1 | 1 | 1 |
| Dividend Yield (%) | 0.00 | 0.79 | 0.63 | 0.8 | 0.29 | 0.58 | 0.3 | 0.23 | 0.29 | 0.24 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 01 Oct 2020 |  Bonus | 3:1 | 30 Sept 2020 | 741.84 | 771.30 |
| 10 Feb 2022 |  Dividend | ₹ 1.00 /share | 09 Feb 2022 | 497.60 | 525.00 |
| 08 Feb 2023 | Dividend | ₹ 1.00 /share | 08 Feb 2023 | 406.10 | 393.45 |
| 06 Feb 2024 | Dividend | ₹ 1.00 /share | 06 Feb 2024 | 535.45 | 519.95 |
| 20 Sept 2024 |  Annual General Meeting | NA | 20 Sept 2024 | 582.80 | 518.60 |
| 24 Oct 2024 |  Quarterly Result Announcement | NA | 24 Oct 2024 | 504.35 | 488.25 |
| 29 Jan 2025 | Quarterly Result Announcement | NA | 29 Jan 2025 | 424.35 | 390.15 |
| 04 Feb 2025 | Dividend | ₹ 1.00 /share | 04 Feb 2025 | 390.15 | 423.40 |
| 06 May 2025 | Quarterly Result Announcement | NA | 06 May 2025 | 351.65 | 355.05 |
| 18 Jul 2025 | Quarterly Result Announcement | NA | 18 Jul 2025 | 480.75 | 515.75 |
| 24 Sept 2025 | Annual General Meeting | NA | 24 Sept 2025 | 469.55 | 513.45 |
| 07 Nov 2025 | Quarterly Result Announcement | NA | 07 Nov 2025 | 502.00 | 488.90 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
Nov 18, 2025
Nov 18, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 10, 2025
Nov 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2025
Nov 08, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 07, 2025
Nov 07, 2025Board Meeting Outcome for Financial Results For The Quarter And Half Year Ended September 30 2025Nov 07, 2025
Nov 07, 2025Financial Results For The Quarter And Half Year Ended September 30 2025Nov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 31, 2025
Oct 31, 2025Board Meeting Intimation for Audited Financial Results For The Quarter And Half Year Ended September 30 2025Oct 31, 2025
Oct 31, 2025Crisil ESG RatingOct 09, 2025
Oct 09, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations")Oct 06, 2025
Oct 06, 2025Closure of Trading WindowSep 29, 2025
Sep 29, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationSep 24, 2025
Sep 24, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 24, 2025
Sep 24, 2025Closure Of Chlorosulfonation Process At PTSCL Section At T-150 Unit Pursuant To Voluntary Closure Directions Of MPCBSep 10, 2025
Sep 10, 2025Commercialization Of Manufacturing Plant Located At SayakhaSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 01, 2025
Sep 01, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 30, 2025
Aug 30, 2025Notice Of 40Th Annual General MeetingAug 30, 2025
Aug 30, 2025Reg. 34 (1) Annual Report.Aug 30, 2025
Aug 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 16, 2025
Aug 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 25, 2025
Jul 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 21, 2025
Jul 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2025
Jul 19, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 19, 2025
Jul 19, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 18, 2025
Jul 18, 2025Appointment Of Secretarial AuditorJul 18, 2025
Jul 18, 2025Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025 And Outcome Of The Meeting Of The Board Of Directors Held On July 18 2025Jul 18, 2025
Jul 18, 2025Financial Results For The Quarter Ended June 30 2025Jul 18, 2025
Jul 18, 2025Reply To The Clarification Sought With Respect To Increase In The Volume Of Security Across The ExchangeJul 16, 2025
Jul 16, 2025Clarification sought from Aarti Drugs LtdJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 15, 2025
Jul 15, 2025Board Meeting Intimation for Audited Financial Results For The Quarter Ended June 30 2025.Jul 15, 2025
Jul 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 12, 2025
Jul 12, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 14, 2025
Jun 14, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 08, 2025
May 08, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth | 1.14% | -32638 | -0.05% | -0.04% | |
 Samco Multi Cap Fund Direct-Growth | 0.41% | 28563 | 0.41% | 0.41% | |
 Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth | 0.22% | 1325 | 0.00% | 0.00% | |
 Groww Nifty Total Market Index Fund Direct - Growth | 0.01% | 5 | 0.00% | 0.00% | |
 Angel One Nifty Total Market Index Fund Direct - Growth | 0.01% | 2 | 0.00% | 0.00% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.13% | 2 | 0.00% | 0.01% | |
| Bandhan Nifty Total Market Index Fund Direct-Growth | 0.01% | -2 | 0.00% | 0.00% | |
 Mirae Asset Nifty Total Market Index Fund Direct-Growth | 0.01% | 1 | 0.00% | 0.00% | |
 DSP Healthcare Fund Direct - Growth | 1.33% | 0 | -0.02% | 0.04% | |
| DSP Small Cap Direct Plan-Growth | 1.86% | 0 | -0.02% | 0.06% | |
| DSP Value Fund Direct - Growth | 0.29% | 0 | -0.01% | -0.02% |
Technical Indicators
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
